Compliance With Nasdaq Periodic Filing Requirement
Rhea-AI Summary
Basel Medical Group (Nasdaq: BMGL) announced that Nasdaq staff determined the company has complied with the periodic filing requirement under Listing Rule 5250(c)(1) for fiscal 2025.
Key point: The Company filed an amended Form 20-F on March 13, 2026, and Nasdaq has resolved the prior deficiency related to the Periodic Filing Rule.
Positive
- Nasdaq confirmed compliance with Listing Rule 5250(c)(1)
- Prior deficiency resolved after amended Form 20-F filed March 13, 2026
Negative
- Company previously had a periodic filing deficiency under Nasdaq rules
Key Figures
Market Reality Check
Peers on Argus
BMGL fell 7.09% while peers showed mixed moves: CCEL up 2.3%, NIVF up 8.12%, CCM down 2.63%, AMS down 1.31%, MODV down 18.59%. This pattern points to stock-specific trading rather than a uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 23 | Nasdaq bid-price notice | Negative | -3.5% | Nasdaq notified BMGL its 30-day closing bid fell below the $1 minimum. |
| Dec 01 | Filing delinquency notice | Negative | -3.5% | Nasdaq flagged BMGL’s Form 20-F as delinquent for lacking an auditor opinion. |
Negative Nasdaq compliance notices in late 2025 and early 2026 were followed by single-digit percentage declines, suggesting sensitivity to listing compliance headlines.
Over the past several months, Basel Medical Group has faced repeated Nasdaq-related compliance issues. On Dec 1, 2025 and Jan 23, 2026, it received delinquency notifications tied to its Form 20-F audit opinion and minimum $1 bid price, with shares declining around these events. The current announcement that Nasdaq now deems the company compliant with the periodic filing requirement resolves the earlier Form 20-F deficiency but does not address the separate minimum bid price notice referenced in January.
Market Pulse Summary
This announcement confirms that Nasdaq now views Basel Medical Group as compliant with its periodic filing requirement under Listing Rule 5250(c)(1), following the amended Form 20-F filed on March 13, 2026. It removes the earlier reporting delinquency flagged in late 2025, though a separate minimum $1 bid-price notice from January 2026 remains relevant. Investors tracking this name may watch future communications on bid-price compliance and any further regulatory updates from Nasdaq.
Key Terms
form 20-f regulatory
listing rule 5250(c)(1) regulatory
periodic filing rule regulatory
AI-generated analysis. Not financial advice.
Singapore, March 24, 2026 (GLOBE NEWSWIRE) -- Basel Medical Group Ltd (Nasdaq: BMGL) (the “Company”) today announced that it has received notification from Nasdaq that based on the Company’s amended annual report on Form 20-F for the fiscal year of 2025, which was filed with the SEC on March 13, 2026, Nasdaq Staff has now determined that the Company has complied with the periodic filing requirement for The Nasdaq Stock Market under Listing Rule 5250(c)(1) (the “Periodic Filing Rule”). Accordingly, the prior deficiency relating to the Periodic Filing Rule has now been resolved.
About Basel Medical Group Ltd
Basel Medical is a Singapore-based provider of orthopedic and trauma services, sports medicine, orthopedic procedures and surgery, as well as neurosurgical treatments, executive health screening services, occupational medicine, rehabilitation, mental and women’s health and general medical practices. Our operations are based in Singapore, with our clinics being located at Suntec City Mall, Macpherson Road, Toa Payoh, Margaret Drive, Tampines, Gateway East and Gleneagles Medical Centre. Over the last 20 years, our group has forged strong and lasting relationships with a large base of corporations, particularly those in the construction, marine and oil & gas industries, which underpin our robust business model. As an medical service provider in Singapore with a track record of over 20 years, we are well-positioned to ride the wave of growth opportunities in the private healthcare industry in Singapore and across Southeast Asia driven by ageing populations, rising income levels, increasing private insurance coverage, increasing expenditure on healthcare, growing sports participation rate and Singapore’s position as a premium destination for healthcare services in Asia. Our management and medical practitioner team comprises a roster of orthopedic and neurosurgery specialists, general practitioners, corporate finance and healthcare partnership specialists. Basel Medical Group Ltd serves as the holding company of our group and we conduct our operations through our operating subsidiaries based in Singapore. For more information, please visit the Company’s website: www.baselmedical.com.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements, which involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”, “will”, “would” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC.
Media Contact:
Basel Medical Group Ltd
+65 6291 9188
FAQ
What did Basel Medical Group (BMGL) announce about Nasdaq compliance on March 24, 2026?
How did BMGL resolve the Nasdaq periodic filing deficiency?
Does Nasdaq’s determination affect BMGL’s listing status on March 24, 2026?
What is the significance for investors that BMGL complied with Listing Rule 5250(c)(1)?
When did BMGL file the amended Form 20-F that led to Nasdaq’s determination?
